Literature DB >> 8639317

Different intravenous administration techniques for 5-fluorouracil. Pharmacokinetics and pharmacodynamic effects.

P A Larsson1, G Carlsson, B Gustavsson, W Graf, B Glimelius.   

Abstract

The pharmacokinetics after 20 min intravenous infusion or a 2 min bolus (push) injection of 5-fluorouracil (500 mg/m2) were studied in 14 colorectal cancer patients. Treatment effects and toxicity related to the administration technique of 5-fluorouracil were retrospectively analysed in 198 colorectal cancer patients. The AUC after bolus injection was 6158 +/- 874 micromol/l*min compared to 3355 +/- 428 micromol/l*min after short-time infusion of 5-fluorouracil (p < 0.01). The mean peak-level after bolus injection was 341 +/- 34 microM versus 161 +/- 17 microM after a short-time infusion (p < 0.01). Patients receiving bolus injections had significantly better treatment result (32% partial remission) than patients receiving infusion (10% partial remissions, p < 0.001). Toxic side-effects were more frequently encountered after bolus injection but subjective improvement was also more frequently experienced by these patients. Bolus 5-fluorouracil push injection rather than a short-time infusion appears to be the more efficient administration technique.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8639317     DOI: 10.3109/02841869609098503

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  7 in total

1.  Phase II trial of PN401, 5-FU, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach: a Southwest Oncology Group study.

Authors:  James H Doroshow; Sheryl McCoy; John S Macdonald; Brian F Issell; Taral Patel; Patrick W Cobb; Kathleen J Yost; James L Abbruzzese
Journal:  Invest New Drugs       Date:  2006-11       Impact factor: 3.850

Review 2.  Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy.

Authors:  Jan H Beumer; Edward Chu; Carmen Allegra; Yusuke Tanigawara; Gerard Milano; Robert Diasio; Tae Won Kim; Ron H Mathijssen; Li Zhang; Dirk Arnold; Katsuki Muneoka; Narikazu Boku; Markus Joerger
Journal:  Clin Pharmacol Ther       Date:  2018-09-11       Impact factor: 6.875

Review 3.  Can pharmacokinetic monitoring improve clinical use of fluorouracil?

Authors:  A M Young; S Daryanani; D J Kerr
Journal:  Clin Pharmacokinet       Date:  1999-06       Impact factor: 6.447

4.  Relationships between body composition parameters and fluorouracil pharmacokinetics.

Authors:  Milena Gusella; Sivia Toso; Eros Ferrazzi; Mariano Ferrari; Roberto Padrini
Journal:  Br J Clin Pharmacol       Date:  2002-08       Impact factor: 4.335

5.  Phase I study of 5-fluorouracil in children and young adults with recurrent ependymoma.

Authors:  Karen D Wright; Vinay M Daryani; David C Turner; Arzu Onar-Thomas; Nidal Boulos; Brent A Orr; Richard J Gilbertson; Clinton F Stewart; Amar Gajjar
Journal:  Neuro Oncol       Date:  2015-11-04       Impact factor: 12.300

Review 6.  Auranofin and its analogs as prospective agents for the treatment of colorectal cancer.

Authors:  Lara Massai; Damiano Cirri; Tiziano Marzo; Luigi Messori
Journal:  Cancer Drug Resist       Date:  2022-01-04

7.  9-ING-41, a Small Molecule Inhibitor of GSK-3β, Potentiates the Effects of Chemotherapy on Colorectal Cancer Cells.

Authors:  Andrey Poloznikov; Sergey Nikulin; Larisa Bolotina; Andrei Kachmazov; Maria Raigorodskaya; Anna Kudryavtseva; Ildar Bakhtogarimov; Sergey Rodin; Irina Gaisina; Maxim Topchiy; Andrey Asachenko; Victor Novosad; Alexander Tonevitsky; Boris Alekseev
Journal:  Front Pharmacol       Date:  2021-12-09       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.